|
⚲
|
| Keyboard |
| Ali Behbahani | |
|---|---|
| Firm | |
| Address | 11757 W Ken Caryl Avenue Suite F, 520 Littleton, CO 80127-3719 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Spyglasspharma Inc | 021-548147 | Director | 75.0 M of 75.0 M |
||
| Tune Therapeutics Inc | 021-536110 | Director | 182.4 M of 208.0 M |
||
| 858 Therapeutics Inc | 021-518431 | Director | 25.2 M of 50.4 M |
||
| Spyglasspharma Inc | 021-486492 | Director | 40.0 M of 90.0 M |
||
| Arcellx Inc | 021-472689 | Director | 100.0 M of 100.0 M |
||
| Launchpad Therapeutics Inc | 021-469187 | Director | 10.0 M of 30.0 M |
||
| NEXO Therapeutics Inc | 021-465438 | Director | 60.0 M of 60.0 M |
||
| Firstlight Bio Inc | 021-442932 | Director | 25.4 M of 25.4 M |
||
| Arcellx Inc | 021-436730 | Director | 10.0 M of 10.0 M |
||
| Cardionomic Inc | 021-415541 | Director | 5.0 M of 11.5 M |
||
| 858 Therapeutics Inc | 021-399747 | Director | 20.0 M of 40.0 M |
||
| Arcellx Inc | 021-395298 | Director | 120.0 M of 120.0 M |
||
| Monte Rosa Therapeutics Inc | 021-393266 | Director | 95.0 M of 95.0 M |
||
| Spyglass Ophthalmics Inc | 021-385257 | Director | 13.7 M of 37.5 M |
||
| Monte Rosa Therapeutics Inc | 021-376612 | Director | 48.0 M of 96.0 M |
||
| Genocea Biosciences Inc | 021-372378 | Director | 75.5 M of 79.9 M |
||
| CVRX Inc | 021-370508 | Director | 50.0 M of 50.0 M |
||
| Minerva Surgical Inc | 021-367681 | Director | 15.0 M of 30.0 M |
||
| CRISPR Therapeutics AG | 021-364701 | Director | 1.0 M of 1.0 M |
||
| Cardionomic Inc | 021-361100 | Director | 15.8 M of 16.8 M |
||
| Black Diamond Therapeutics Inc | 021-354957 | Director | 85.0 M of 85.0 M |
||
| Minerva Surgical Inc | 021-354743 | Director | 10.0 M of 10.5 M |
||
| Nkarta Inc | 021-348219 | Director | 43.9 M of 114.6 M |
||
| Arcellx Inc | 021-347172 | Director | 42.8 M of 83.7 M |
||
| Spyglass Ophthalmics Inc | 021-341181 | Director | 6.0 M of 6.0 M |
||
| Minerva Surgical Inc | 021-339780 | Director | 10.2 M of 10.5 M |
||
| Genocea Biosciences Inc | 021-333740 | Director | 12.1 M of 15.0 M |
||
| Oyster Point Pharma Inc | 021-333703 | Director | 85.0 M of 93.0 M |
||
| Solace Therapeutics Inc | 021-332570 | Director | 1.9 M of 2.1 M |
||
| Minerva Surgical Inc | 021-329621 | Director | 9.2 M of 10.0 M |
||
| Black Diamond Therapeutics Inc | 021-329523 | Director | 44.2 M of 87.2 M |
||
| Cardionomic Inc | 021-311249 | Director | 9.0 M of 9.6 M |
||
| Minerva Surgical Inc | 021-307556 | Director | 10.0 M of 20.0 M |
||
| Oyster Point Pharma Inc | 021-297412 | Director | 28.6 M of 43.1 M |
||
| Ivantis Inc | 021-278940 | Director | 25.0 M of 25.0 M |
||
| CRISPR Therapeutics AG | 021-273840 | Director | 35.0 M of 35.0 M |
||
| Solace Therapeutics Inc | 021-270110 | Director | 13.0 M of 20.0 M |
||
| Rotation Medical Inc | 021-268554 | Director | 8.0 M of 8.0 M |
||
| CVRX Inc | 021-264929 | Director | 75.3 M of 93.0 M |
||
| Minerva Surgical Inc | 021-254790 | Director | 15.0 M of 15.0 M |
||
| Cardionomic Inc | 021-249544 | Director | 21.8 M of 21.8 M |
||
| Adaptimmune Ltd | 021-225667 | Director | 103.8 M of 103.8 M |
||
| Minerva Surgical Inc | 021-225123 | Director | 25.5 M of 25.5 M |
||
| Rotation Medical Inc | 021-220679 | Director | 21.7 M of 21.7 M |
||
| Oculeve Inc | 021-213802 | Director | 16.6 M of 16.6 M |
||
| CVRX Inc | 021-199681 | Director | 29.6 M of 45.0 M |
||
| Rotation Medical Inc | 021-197480 | Director | 5.5 M of 5.5 M |
||
| Ivantis Inc | 021-191569 | Director | 58.9 M of 71.4 M |
||
| Minerva Surgical Inc | 021-188864 | Director | 20.0 M of 20.0 M |
||
| Oculeve Inc | 021-186287 | Director | 7.6 M of 7.6 M |
||
| Prospex Medical III Inc | 021-166174 | Director | 1.5 M of 4.0 M |
||
| Minerva Surgical Inc | 021-160714 | Director | 26.2 M of 26.2 M |
||
| Rotation Medical Inc | 021-158374 | Director | 10.0 M of 15.0 M |
||
| Denali Medical II Inc | 021-140685 | Director | 4.0 M of 4.6 M |
||
| Rotation Medical Inc | 021-99328 | Director | 3.9 M of 4.4 M |
||
| NEA Management Company LLC | |||||
| NEA CH SPV LP | 021-513878 | Executive Officer | 65.0 M of 65.0 M |
94.7 M | |
| NEA RP SPV LP | 021-505950 | Executive Officer | 244.6 M of 244.6 M |
376.0 M | |
| NEA TS 2024 SPV LP | 021-516399 | Executive Officer | 155.0 M of 155.0 M |
215.4 M | |
| NEA Secondary Opportunity Fund LP | 021-519116 | Executive Officer | 468.2 M of 468.2 M |
1,026.6 M | |
| NEA SH SPV LP | 021-481086 | Executive Officer | 12.5 M of 12.5 M |
18.8 M | |
| NEA 18 Venture Growth Equity LP | 021-420921 | Executive Officer | 2,328.8 M of 3,700.0 M |
4,540.1 M | |
| New Enterprise Associates 18 LP | 021-420874 | Executive Officer | 2,845.3 M of 2,900.0 M |
5,830.9 M | |
| NEA BH SPV II LP | 021-374899 | Executive Officer | 67.3 M of 67.3 M |
0.9 M | |
| NEA BH SPV LP | 021-355891 | Executive Officer | 129.3 M of 129.3 M |
2.4 M | |
| New Enterprise Associates 17 LP | 021-333845 | Executive Officer | of 3,600.0 M |
4,507.4 M | |